Literature DB >> 32611256

Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.

Claudio Galvao de Castro1, Lauro Jose Gregianin2,3, Jan A Burger4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32611256     DOI: 10.1080/10428194.2020.1786559

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  2 in total

1.  Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways.

Authors:  Haofeng Lu; Lin Zhou; Hongping Zuo; Wenjin Le; Jianfei Hu; Tiequan Zhang; Mi Li; Yufeng Yuan
Journal:  Pharmacol Res Perspect       Date:  2022-06

2.  Ivermectin as a potential therapeutic in COVID-19.

Authors:  Juan Segura-Aguilar; Yousef Tizabi
Journal:  Clin Pharmacol Transl Med       Date:  2020-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.